Cramer: Hewlett's Back
Health Care: Drugs
Hemispherx Biopharma Inc. (HEB: AMEX)
$0.20 0.00 | 0.25%
05/23/13 - 03:59 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 2.21M | 3.10M | 2.92M | 58.07M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 453.00K | 897.00K | 787.00K | 0.00 |
| Other Current Assets | 322.00K | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 44.73M | 31.79M | 36.67M | 58.40M |
| Property, Plant & Equipment, Gross | 8.96M | 9.78M | 7.92M | 6.99M |
| Accumulated Depreciation & Depletion | 3.66M | 3.02M | 2.56M | 2.15M |
| Property, Plant & Equipment, Net | 5.29M | 6.76M | 5.36M | 4.84M |
| Intangibles | 1.03M | 863.00K | 794.00K | 830.00K |
| Other Non-Current Assets | 6.64M | 4.10M | 8.85M | 921.00K |
| Total Non-Current Assets | 12.97M | 11.73M | 15.01M | 6.59M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 57.70M | 43.51M | 51.68M | 64.99M |
| Accounts Payable | 2.16M | 1.68M | 1.33M | 1.29M |
| Short Term Debt | 46.00K | 1.74M | 61.00K | 0.00 |
| Other Current Liabilities | 7.05M | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 12.65M | 5.07M | 2.83M | 2.62M |
| Long Term Debt | 295.00K | 380.00K | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 2.80M | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 350.00K | 479.00K | 2.90M | 0.00 |
| Total Liabilities | 13.00M | 5.55M | 5.73M | 2.62M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 44.70M | 37.96M | 45.95M | 62.38M |
| Common Par | 166.00K | 136.00K | 135.00K | 133.00K |
| Additional Paid In Capital | 288.67M | 264.96M | 264.51M | 273.09M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -244.09M | -226.74M | -217.72M | -210.85M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -43.00K | -389.00K | -974.00K | 0.00 |
| Total Capitalization | 45.00M | 38.34M | 45.95M | 62.38M |
| Total Equity | 44.70M | 37.96M | 45.95M | 62.38M |
| Total Liabilities & Stock Equity | 57.70M | 43.51M | 51.68M | 64.99M |
| Total Common Shares Outstanding | 166.49M | 135.64M | 132.79M | 132.79M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 141.02M | 135.43M | 134.02M | 109.51M |
| Diluted Weighted Shares Outstanding | 141.02M | 135.43M | 134.02M | 109.51M |
| Number of Employees | 34 | 47 | 29 | 32 |
| Number of Part-Time Employees | 3 | 12 | 27 | 12 |
Portfolios with HEB
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorEarnings Short Squeeze Play...
- UserBio
- ContributorBreakout Stocks Of The Week...
- Usermoney maker
- Usersuziltd
- Uservlady 1
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
Latest HEB Headlines from TheStreet
- Hemispherx Biopharma Announces Financial Results For The Three Months Ended March 31, 2013 05.08.13 | 03:05 pm
- The 5 Dumbest Things on Wall Street This Week: May 3 05.03.13 | 08:05 am
- 5 Dumbest Things on Wall Street
05.03.13 | 05:05 am - Hemispherx Biopharma Announces Financial Results For The Year Ended December 31, 2012 03.18.13 | 03:03 pm
- Hemispherx Biopharma Gains Broad Treatment Expansion For Alferon N Injection(R) In Argentina 03.04.13 | 08:03 am
- Hemispherx Biopharma Receives Complete Response Letter From FDA On Ampligen(R) New Drug Application For Chronic Fatigue Syndrome 02.04.13 | 07:02 pm
- Biotech Stock Mailbag: Celsion, Navidea, AP Pharma, Sarepta 02.01.13 | 07:02 am
- FDA Advisory Committee Makes Recommendations On Ampligen (R) For Chronic Fatigue Syndrome 12.21.12 | 02:12 pm
- Hemispherx Lied To Investors And SEC About Ampligen 12.18.12 | 10:12 am
- Biotech Stock Mailbag: Celsion Short Thesis, Hemispherx 12.14.12 | 06:12 am
Press Releases for HEB
- UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Hemispherx Biopharma, Inc. Of Class Action Lawsuit And The Deadline Of February 22, 2013 To Seek A Lead Plaintiff Position - Business Wire 02.20.13 | 03:02 pm
- Cohen Milstein Sellers & Toll PLLC Continues To Investigate Hemispherx Biopharma, Inc. Following The FDA’s Rejection Of The Ampligen New Drug Application - Business Wire 02.05.13 | 05:02 pm
- Pittsburgh Law Office Of Alfred G. Yates Jr., P.C. Files Class Action Lawsuit On Behalf Of Shareholders Of Groupon (GRPN) And Announces Investigations Of Diodes (DIOD), Hemispherex Biopharma (HEB), ISIS Pharmaceuticals (ISIS), K-Swiss (KSWS), MAP Pharmaceuticals (MAPP), Neptune Technologies & Bioressources (NEPT), SeaCube Container Leasing (BOX), Spirit AeroSystems Holdings (SPR), Verisign (VRSN), And Yum! Brands (YUM) - PR Newswire 01.23.13 | 03:01 pm
- Robbins Arroyo LLP Announces The Filing Of A Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc. - PR Newswire 01.17.13 | 07:01 pm
- Cohen Milstein Sellers & Toll PLLC Announces The Investigation Of Hemispherx Biopharma, Inc. - Business Wire 01.16.13 | 05:01 pm
- Faruqi & Faruqi, LLP Encourages Investors Who Suffered $50,000 Or More In Losses Investing In Hemispherx Biopharma, Inc. To Contact The Firm - PR Newswire 12.28.12 | 08:12 pm
- Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Hemispherx Biopharma, Inc. - PR Newswire 12.19.12 | 08:12 am
- Securities Class Action Filed By Shepherd, Finkelman, Miller & Shah, LLP On Behalf Of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 And November 2, 2009 - PR Newswire 12.08.09 | 04:12 pm
Partner Headlines for HEB
- Stock Watch Wednesday, 19 December - Seeking Alpha 12.19.12 | 09:12 am
- 3 Stocks With High Alphas: Acadia, Hemispherx, And Vringo - Seeking Alpha 11.08.12 | 09:11 am
- Oink Oink: Profit From The Return Of Swine Flu - Benzinga 01.12.12 | 01:01 pm
- UPDATE 1-Hemispherx awarded $188 mln in "illegal" takeover suit - Reuters 08.18.10 | 12:08 pm
